R. Esteban-Fabró

Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma

V. Mazzaferro, I. Salaverria, L. Bassaganyas, 2020, Clinical Cancer Research.

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.

T. Pawlik, G. Castellano, L. Bassaganyas, 2020, Journal of hepatology.

CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications

L. Bassaganyas, J. Llovet, M. Vila-Casadesús, 2020, eLife.

CNApp: quantification of genomic copy number alterations in cancer and integrative analysis to unravel clinical implications

L. Bassaganyas, J. Llovet, M. Vila-Casadesús, 2018 .

CNApp: a web-based tool for integrative analysis of genomic copy number alterations in cancer

L. Bassaganyas, J. Llovet, M. Vila-Casadesús, 2018, bioRxiv.

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

M. Esteller, V. Mazzaferro, L. Bassaganyas, 2019, British Journal of Cancer.

CXCR2 inhibition enables NASH-HCC immunotherapy

S. Barry, J. Llovet, David McDonald, 2022, Gut.

Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma.

V. Mazzaferro, J. Llovet, F. Miró-Mur, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

M. Esteller, V. Mazzaferro, L. Bassaganyas, 2019, British Journal of Cancer.